Information de reference pour ce titreAccession Number: | 00002953-199805000-00020.
|
Author: | Kimerling, Michael E. MD; Phillips, Penny RN; Patterson, Patricia MD; Hall, Marilyn BSc; Robinson, C. Andrew PhD; Dunlap, Nancy E. MD, FCCP
|
Institution: | *From the Division of International Health, School of Public Health (Dr. Kimerling), the Division of Pulmonary and Critical Care Medicine (Drs. Dunlap, Patterson, and Kimerling and Ms. Phillips), the Department of Pathology (Dr. Robinson and Ms. Hall), School of Medicine, University of Alabama at Birmingham. Partial funding was provided through CDC Cooperative Agreement C60117087. Manuscript received July 29, 1997; revision accepted January 28, 1998. Reprint requests: Michael E. Kimerling, MD, Dept of International Health, UAB School of Public Health, 302A Tidwell Hall, 720 South 20th Street, Birmingham, AL 35294-0008.
|
Title: | Low Serum Antimycobacterial Drug Levels in Non-HIV-Infected Tuberculosis Patients*.[Article]
|
Source: | Chest. 113(5):1178-1183, May 1998.
|
Abstract: | Background: Despite the use of directly observed therapy (DOT) by tuberculosis control programs, patient treatment failure, relapse, and acquired drug resistance remain problematic in a small number. We investigated serum drug levels in non-HIV-infected tuberculosis patients who were receiving DOT by the health department and did not respond to treatment as expected.
Methods: The indications for checking levels were as follows: (1) slow clinical response or failure to convert the sputum culture within 12 weeks; (2) treatment failure, early disease relapse <13 months since being declared cured; (3) relapse, late disease reactivation >or=to13 months since being declared cured; and (4) acquired drug resistance while receiving DOT. Baseline characteristics of control subjects who responded to therapy as expected were compared. Venous blood for analysis was obtained at 2 h after directly observed ingestion and measured by high-performance liquid chromatography.
Results: Twenty-four patients receiving daily or twice-weekly standard therapy with isoniazid (INH, 300 or 900 mg) and rifampin (RMP, 600 mg) were identified; 22 had drug levels evaluated at 2 h. For INH, 15 of 22 patients (68%) had levels less than the reported target range. For RMP, 14 of 22 patients (64%) had low levels. Among the 14 patients receiving INH, 900 mg, and RMP, 600 mg, 4 (29%) had very low levels of both. Use of a combination INH/RMP tablet was associated with lower INH levels (p=0.04); however, RMP levels were higher (p<0.02). Alcohol use was associated with significantly higher RMP (p<0.01) serum concentrations.
Conclusions: Important questions remain concerning the utility and timing of serum drug measurements. However, if a patient is not responding to therapy as expected and one is assured that the Mycobacterium tuberculosis organism is susceptible to the drugs given and that the patient is taking the medication as prescribed, drug level monitoring should be considered.
(CHEST 1998; 113:1178-83)
Copyright (C) 1998 by the American College of Chest Physicians
|
References: | 1. Berning SE, Huitt GA, Iseman MD, et al. Malabsorption of antituberculosis medications by a patient with AIDS [letter]. N Engl J Med 1992; 327:1817-18
2. Peloquin CA, MacPhee AA, Berning SE. Malabsorption of antimycobacterial medications [letter]. N Engl J Med 1993; 329:1122-23
3. Gordon SM, Horsburgh CR, Peloquin CA, et al. Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease. J Infect Dis 1993; 168:1559-62
4. Patel KB, Belmonte R, Crowe HM. Drug malabsorption and resistant tuberculosis in HIV-infected patients [letter]. N Engl J Med 1995; 332:336-37
5. Holdiness MR. Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet 1984; 9:511-44
6. Peloquin CA. Therapeutic drug monitoring: principles and application in mycobacterial infections. Drug Ther 1992; 22:31-36
7. Peloquin CA. Pharmacology of the antimycobacterial drugs. Med Clin North Am 1993; 77:1253-62
8. Gaitonde CD, Pathak PV. Rapid liquid chromatographic method for the estimation of isoniazid and pyrazinamide in plasma and urine. J Chromatogr B Biomed Appl 1990; 532:418-23
9. El-Yazigi A, Raines DA. Simultaneous microdetermination of rifampin, deacetylrifampin, isoniazid, and acetylisoniazid in plasma by liquid chromatography with dual electrochemical and spectrophotometric detection. Pharm Res 1992; 9:812-16
10. Conover WJ. Practical nonparametric statistics. 2nd ed. New York: John Wiley, 1980
11. Weber WW, Hein DW. Clinical pharmacokinetics of isoniazid. Clin Pharmacokinet 1979; 4:401-22
12. Buniva G, Pagani V, Carozzi A. Bioavailability of rifampicin capsules. Int J Clin Pharmacol Ther Toxicol 1983; 21:404-09
13. Notterman DA, Nardi M, Saslow JG. Effect of dose formulation on isoniazid absorption in two young children. Pediatrics 1986; 77:850-52
14. Borcherding SM, Baciewicz AM, Self TH. Update on rifampin drug interactions II. Arch Intern Med 1992; 152:711-16
15. Cavenaghi R. Rifampicin raw material characteristics and their effect on bioavailability. Bull Int Union Tuberc Lung Dis 1989; 64:36-37
16. Acocella G. Human bioavailability studies. Bull Int Union Tuberc Lung Dis 1989; 64:38-41
17. Sbarbaro JA. A challenge-to our practices and to our principles. Tuber Lung Dis 1996; 77:2-3
|
Language: | English.
|
Document Type: | Clinical Investigations: Tuberculosis.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0012-3692
|
NLM Journal Code: | 0231335, d1c
|
Annotation(s) | |
|
|